Gondokesumo Marisca Evalina, Purnamayanti Anita, Hanum Puri Safitri, Santosa Winnie Nirmala, Wardhana Ardyan Prima, Avanti Christina
Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia.
Faculty of Medicine, University of Surabaya, Surabaya, Indonesia.
Clin Exp Vaccine Res. 2023 Jul;12(3):224-231. doi: 10.7774/cevr.2023.12.3.224. Epub 2023 Jul 31.
The Sinovac and AstraZeneca vaccines are the primary coronavirus disease 2019 vaccines in Indonesia. Antibody levels in vaccine-injected individuals will decline substantially over time, but data supporting the duration of such responses are limited. Therefore, this study aims to quantitatively evaluate antibody responses resulting from the completion of Sinovac and AstraZeneca administration in Indonesian adults.
Participants were divided into two groups based on their vaccine type. Both groups were then assessed on the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (anti-SRBD) concentrations. The anti-SRBD level was measured using Elecsys anti-SARS-CoV-2 S assay and analyzed every month until 3 months after the second vaccination.
The results presented significant differences (p=0.000) in immunoglobulin G (IgG) titers among the vaccines' measurement duration, where all samples observed a decrease in IgG titers over time. The mean titer levels of anti-SRBD IgG in the group given Sinovac were high in the first month after vaccination and decreased by 55.7% in 3 months. AstraZeneca showed lesser immune response with a slower decline rate. Adverse effects following immunization (AEFI) showed that systemic reactions are the most reported in both vaccines, with a higher percentage in the second dose of AstraZeneca type vaccines.
Sinovac induced more significant titers of anti-SRBD IgG 1 month after the second dose but generated fewer AEFIs. In contrast, AstraZeneca generated more AEFIs, in mild to moderate severity, but provided lower levels of anti-SRBD IgG.
科兴疫苗和阿斯利康疫苗是印度尼西亚主要的2019冠状病毒病疫苗。接种疫苗个体的抗体水平会随着时间大幅下降，但支持这种反应持续时间的数据有限。因此，本研究旨在定量评估印度尼西亚成年人完成科兴疫苗和阿斯利康疫苗接种后的抗体反应。
参与者根据疫苗类型分为两组。然后对两组的抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域（抗-SRBD）浓度进行评估。使用罗氏电化学发光法抗SARS-CoV-2 S检测法测量抗-SRBD水平，并每月进行分析，直至第二次接种后3个月。
结果显示，在疫苗的测量期间，免疫球蛋白G（IgG）滴度存在显著差异（p=0.000），所有样本的IgG滴度均随时间下降。接种科兴疫苗组的抗-SRBD IgG平均滴度水平在接种后第一个月较高，3个月内下降了55.7%。阿斯利康疫苗的免疫反应较弱，下降速度较慢。免疫接种后不良反应（AEFI）显示，两种疫苗中最常报告的是全身反应，阿斯利康疫苗第二剂的报告比例更高。
科兴疫苗在第二剂接种后1个月诱导产生的抗-SRBD IgG滴度更显著，但产生的免疫接种后不良反应较少。相比之下，阿斯利康疫苗产生的免疫接种后不良反应更多，程度为轻度至中度，但抗-SRBD IgG水平较低。
